Radeas LLC

Radeas LLC was paid $34.31M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 69% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#9 of 128

Median peer was paid$268K

This provider vs. median128×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	69,137	$2.62M
2019	111,021	$4.78M
2020	94,665	$4.85M
2021	100,180	$5.74M
2022	121,201	$6.23M
2023	106,503	$5.06M
2024incomplete	94,316	$5.03M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	69%	270,471	166,814	$23.53M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	174,942	114,056	$4.62M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	8.1%	36,771	24,605	$2.80M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.9%	34,069	17,107	$1.35M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	2.0%	14,718	8,982	$692K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.8%	11,442	9,051	$609K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	12,426	7,453	$185K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	3,624	1,271	$94K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,393	2,088	$39K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	682	605	$39K
80050	General health panel	<1%	4,246	3,771	$27K
80061	Lipid panel	<1%	2,986	2,598	$24K

116 more codes

82607		<1%	1,585	$17K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,059	$15K
84481		<1%	1,426	$15K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	345	$14K
80074		<1%	1,117	$13K
80053	Comprehensive metabolic panel	<1%	1,558	$10K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,593	$9K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	432	$9K
84443	Thyroid stimulating hormone (TSH)	<1%	735	$9K
87481		<1%	473	$9K
84439		<1%	1,895	$8K
83992		<1%	4,286	$7K
80361		<1%	2,811	$6K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	44	$6K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	121	$5K
80364		<1%	2,865	$4K
82746		<1%	422	$4K
86803		<1%	564	$4K
80354		<1%	4,494	$4K
80348		<1%	4,502	$4K
80357		<1%	4,228	$4K
80355		<1%	4,328	$4K
80366		<1%	4,297	$4K
80373		<1%	3,286	$4K
80349		<1%	4,301	$4K
80372		<1%	4,424	$4K
80358		<1%	4,379	$4K
80353		<1%	4,426	$4K
80359		<1%	4,452	$4K
80347		<1%	592	$4K
80356		<1%	4,399	$4K
80365		<1%	2,831	$4K
80350		<1%	3,946	$4K
80324		<1%	4,075	$4K
82728		<1%	584	$3K
86702		<1%	1,159	$3K
80371		<1%	2,766	$3K
80346		<1%	4,221	$3K
87529		<1%	78	$3K
80370		<1%	691	$3K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	100	$3K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	74	$3K
86701		<1%	1,174	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	59	$2K
80360		<1%	3,950	$2K
83540		<1%	567	$2K
80336		<1%	376	$2K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	142	$2K
80335		<1%	3,302	$2K
80363		<1%	1,825	$2K
80374		<1%	339	$2K
87653		<1%	450	$2K
87640		<1%	455	$2K
87500		<1%	453	$2K
87641		<1%	453	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	102	$1K
84207		<1%	45	$1K
80369		<1%	4,027	$1K
83690		<1%	1,175	$1K
80321		<1%	254	$1K
82150		<1%	1,178	$1K
86141		<1%	172	$1K
87511		<1%	25	$973.48
86703		<1%	198	$905.88
80367		<1%	2,562	$867.26
81025		<1%	312	$813.00
87340		<1%	243	$790.15
82525		<1%	75	$765.31
86592		<1%	222	$732.01
84630		<1%	73	$689.56
84403		<1%	99	$601.48
83735		<1%	557	$566.51
87522	Neg quan hep c or qual rna	<1%	36	$509.45
83090		<1%	66	$487.68
82977		<1%	113	$486.22
82390		<1%	58	$443.14
86617		<1%	45	$418.90
86611		<1%	47	$360.16
86704		<1%	45	$356.70
80178		<1%	113	$310.77
83921		<1%	14	$256.38
36415	Collection of venous blood by venipuncture	<1%	281	$237.04
80164		<1%	14	$200.40
80320		<1%	249	$148.64
82248		<1%	38	$131.97
82565		<1%	187	$122.66
82610		<1%	26	$121.92
86709		<1%	128	$112.60
80332		<1%	85	$110.60
80326		<1%	228	$108.84
86705		<1%	126	$105.93
80305		<1%	154	$99.27
80048	Basic metabolic panel (calcium, ionized)	<1%	15	$93.89
87563		<1%	17	$82.42
87631		<1%	13	$71.32
80345		<1%	712	$31.83
80368		<1%	370	$31.83
84550		<1%	13	$27.03
87541		<1%	13	$17.55
87486		<1%	13	$17.55
87581		<1%	13	$17.55
85652		<1%	13	$15.78
80323		<1%	944	$15.38
80325		<1%	37	$10.61
81001		<1%	15	$9.89
82570		<1%	22	$4.86
82043		<1%	22	$2.20
80334		0%	222	$0.00
80338		0%	233	$0.00
80337		0%	222	$0.00
80344		0%	173	$0.00
85004		0%	15	$0.00
80362		0%	19	$0.00
85048		0%	14	$0.00
80352		0%	221	$0.00
80333		0%	21	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRADFORD, PHIL (LAB DIRECTOR)